title: Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.
abstract: The dangers of phaeochromocytomas are mainly due to the capability of these neuroendocrine tumours to secrete large quantities of vasoactive catecholamines, thereby increasing blood pressure and causing other related adverse events or complications. Phaeochromocytomas are often missed, sometimes only becoming apparent during therapeutic interventions that provoke release or interfere with the disposition of catecholamines produced by the tumours. Because phaeochromocytomas are rare, evidence contraindicating use of specific drugs is largely anecdotal or based on case reports. The heterogeneous nature of the tumours also makes adverse reactions highly variable among patients. Some drugs, such as dopamine D(2) receptor antagonists (e.g. metoclopramide, veralipride) and beta-adrenergic receptor antagonists (beta-blockers) clearly carry high potential for adverse reactions, while others such as tricyclic antidepressants seem more inconsistent in producing complications. Other drugs capable of causing adverse reactions include monoamine oxidase inhibitors, sympathomimetics (e.g. ephedrine) and certain peptide and corticosteroid hormones (e.g. corticotropin, glucagon and glucocorticoids). Risks associated with contraindicated medications are easily minimised by adoption of appropriate safeguards (e.g. adrenoceptor blockade). Without such precautions, the state of cardiovascular vulnerability makes some drugs and manipulations employed during surgical anaesthesia particularly dangerous. Problems arise most often when drugs or therapeutic procedures are employed in patients in whom the tumour is not suspected. In such cases, it is extremely important for the clinician to recognise the possibility of an underlying catecholamine-producing tumour and to take the most appropriate steps to manage and treat adverse events and clinical complications.
authors.affiliation: Department of Clinical Chemistry and Laboratory Medicine, University of Dresden, Dresden, Germany. Graeme.Eisenhofer@uniklinikum-dresden.de
authors.forename: Graeme
authors.initials: G
authors.lastname: Eisenhofer
authors.forename: Graham
authors.initials: G
authors.lastname: Rivers
authors.forename: Alejandro L
authors.initials: AL
authors.lastname: Rosas
authors.forename: Zena
authors.initials: Z
authors.lastname: Quezado
authors.forename: William M
authors.initials: WM
authors.lastname: Manger
authors.forename: Karel
authors.initials: K
authors.lastname: Pacak
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000150:complications* / Q000378:metabolism; D000818:Animals; D002395:Catecholamines / Q000378:metabolism / Q000502:physiology*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D010673:Pheochromocytoma / Q000150:complications* / Q000378:metabolism
chemical_list: D002395:Catecholamines